Zymeworks Announces Participation in Upcoming Investor Conferences
Key Highlights
- ➤Zymeworks management to attend Evercore Healthcare Conference on November 30
- ➤Zymeworks management to attend Citi’s 2026 Global Healthcare Conference on December 1
- ➤Evercore fireside chat scheduled for 2:10 pm Eastern Time
- ➤Citi fireside chat scheduled for 3:40 pm ET
VANCOUVER, British Columbia, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced will participate in the following upcoming investor conferences: * Evercore Healthcare Conference: Management will participate in one-on-one meetings and a fireside chat on November 30 at 2:10 pm Eastern Time (ET) in Miami, FL * Citi’s 2026 Global Healthcare Conference: Management will participate in one-on-one meetings and a fireside chat on December 1 at 3:40 pm ET in Miami, FL A live webcast of certain fireside chats will be available in the Investors section of the Zymeworks website at www.zymeworks.com, and a replay will be available following the events.
Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets designed to generate durable cash flows while advancing innovative medicines for difficult-to-treat diseases. The Company’s asset and royalty aggregation strategy combines a growing portfolio of commercial and near-commercial assets, including YUPELRI® (revefenacin), with a differentiated internal research and development engine. Zymeworks’ portfolio also includes Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using Zymeworks’ proprietary antibody engineering technologies.
Get started
Create a free account to read the full story.
